UK committee urges break clause on Palantir’s £330M NHS data contract
A UK parliamentary committee has called Palantir’s role in the public sector an “unacceptable point of weakness” and urged the government to break its NHS contract with the American company. The Science, Innovation and Technology Committee singled out Palantir as the technology provider it found most concerning, arguing that the UK was at risk of […]<br /> This story continues at The Next Web [...]
Rating
Innovation
Pricing
Technology
Usability
We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.
The UK is reviewing its £330M NHS deal with Palantir, and may pull the plug in 2027
The British government has put its most contentious health-tech contract on notice. It is now formally reviewing the NHS’s £330mn deal with Palantir, and weighing whether to walk away in 2027. Tech [...]
NHS England gives Palantir contractors broader access to patient data
A leaked internal briefing note describes a new admin role on the £330m Federated Data Platform that lets external staff bypass case-by-case data approvals. Patient groups and Labour MPs have called [...]
NHS England rolls out Microsoft 365 Copilot to 505,000 staff after trial reports 43 minutes saved per day
NHS England is giving more than 505,000 clinicians and support staff access to Microsoft 365 Copilot in what will be the largest AI deployment in healthcare globally. The rollout follows a pilot acros [...]
UK NHS chief champions Palantir’s 'outstanding results’ in England, pushes for deeper rollout despite growing staff concerns
NHS staff are concerned about Palantir access to database containing details on 1.5 million staff, but NHS Data Chief Ming Tang says her team needs to 'maintain our focus' in the face of sta [...]
Palantir's 'unlimited access' to patient data — we examine the US tech giant's controversial £330 million contract with the NHS
While the NHS has just granted Palantir "unlimited access" to patient data, the relationship between the UK public health sector and the controversial American firm dates back to 2020. Here& [...]